DE60107399D1 - Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin - Google Patents
Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrinInfo
- Publication number
- DE60107399D1 DE60107399D1 DE60107399T DE60107399T DE60107399D1 DE 60107399 D1 DE60107399 D1 DE 60107399D1 DE 60107399 T DE60107399 T DE 60107399T DE 60107399 T DE60107399 T DE 60107399T DE 60107399 D1 DE60107399 D1 DE 60107399D1
- Authority
- DE
- Germany
- Prior art keywords
- desglymidodrine
- midodrine
- controlled release
- desglymidodrin
- midodrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960001094 midodrine Drugs 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- PTKSEFOSCHHMPD-UHFFFAOYSA-N midodrine Chemical compound COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-UHFFFAOYSA-N 0.000 title 1
- VFRCNXKYZVQYLX-UHFFFAOYSA-N deglymidodrine Chemical compound COC1=CC=C(OC)C(C(O)CN)=C1 VFRCNXKYZVQYLX-UHFFFAOYSA-N 0.000 abstract 5
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 abstract 3
- 239000002207 metabolite Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002746 orthostatic effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000549 | 2000-03-31 | ||
| US20378300P | 2000-05-12 | 2000-05-12 | |
| PCT/DK2001/000213 WO2001074334A1 (en) | 2000-03-31 | 2001-03-29 | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60107399D1 true DE60107399D1 (de) | 2004-12-30 |
Family
ID=26068806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60107399T Expired - Lifetime DE60107399D1 (de) | 2000-03-31 | 2001-03-29 | Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1267841B1 (de) |
| JP (1) | JP2003528909A (de) |
| CN (1) | CN1422150A (de) |
| AT (1) | ATE283036T1 (de) |
| AU (1) | AU2001246388A1 (de) |
| CA (1) | CA2403886A1 (de) |
| DE (1) | DE60107399D1 (de) |
| EE (1) | EE200200556A (de) |
| NO (1) | NO20024673L (de) |
| WO (1) | WO2001074334A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1289493A1 (de) * | 2000-05-26 | 2003-03-12 | Nycomed Austria GmbH | Pharmazeutische zusammensetzungen enthaltend desglymidodrine als wirkstoff |
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| JP7057365B2 (ja) * | 2016-09-30 | 2022-04-19 | ゼナメッド コーポレーション | ミドドリンの組成物およびその使用方法 |
| WO2018074879A1 (ko) * | 2016-10-21 | 2018-04-26 | 주식회사 셀버틱스 | 미도드린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 및/또는 고지혈증의 예방 또는 치료용 약학적 조성물 |
| US11013702B2 (en) | 2017-10-10 | 2021-05-25 | Vertice Pharma, Llc | Midodrine hydrochloride oral solution and uses thereof |
| US12213953B2 (en) | 2017-12-22 | 2025-02-04 | Xenamed Corp. | Extended release midodrine hydrochloride compositions and methods of use |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| KR102151051B1 (ko) * | 2019-01-10 | 2020-09-02 | 고려대학교 산학협력단 | 당뇨병성 백내장 치료 또는 예방용 조성물 |
| WO2022157633A1 (en) * | 2021-01-20 | 2022-07-28 | Cadila Healthcare Limited | Enantiomerically pure desglymidodrine and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3417576A1 (de) * | 1984-05-11 | 1985-11-14 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung |
| AT383270B (de) * | 1984-05-15 | 1987-06-10 | Chemie Linz Ag | Verfahren zur herstellung von oralen retardformen des alpha-(2,5-dimethoxy-phenyl)-betaglycinamido|thanols |
| EP0423484B1 (de) * | 1989-10-16 | 1993-11-03 | PCD-Polymere Gesellschaft m.b.H. | Pressling mit retardierter Wirkstofffreisetzung |
-
2001
- 2001-03-29 AU AU2001246388A patent/AU2001246388A1/en not_active Abandoned
- 2001-03-29 AT AT01919228T patent/ATE283036T1/de not_active IP Right Cessation
- 2001-03-29 EP EP01919228A patent/EP1267841B1/de not_active Expired - Lifetime
- 2001-03-29 JP JP2001572079A patent/JP2003528909A/ja active Pending
- 2001-03-29 WO PCT/DK2001/000213 patent/WO2001074334A1/en not_active Ceased
- 2001-03-29 CA CA002403886A patent/CA2403886A1/en not_active Abandoned
- 2001-03-29 EE EEP200200556A patent/EE200200556A/xx unknown
- 2001-03-29 CN CN01807541A patent/CN1422150A/zh active Pending
- 2001-03-29 DE DE60107399T patent/DE60107399D1/de not_active Expired - Lifetime
-
2002
- 2002-09-30 NO NO20024673A patent/NO20024673L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE283036T1 (de) | 2004-12-15 |
| EP1267841B1 (de) | 2004-11-24 |
| NO20024673L (no) | 2002-11-27 |
| WO2001074334A1 (en) | 2001-10-11 |
| CA2403886A1 (en) | 2001-10-11 |
| JP2003528909A (ja) | 2003-09-30 |
| NO20024673D0 (no) | 2002-09-30 |
| EP1267841A1 (de) | 2003-01-02 |
| CN1422150A (zh) | 2003-06-04 |
| AU2001246388A1 (en) | 2001-10-15 |
| EE200200556A (et) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200201044A1 (ru) | Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| EA200701131A1 (ru) | Гелеобразная препаративная форма капсаициноида и способы её применения | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| EP2248519A3 (de) | Nichtmukoadhäsive Filmdosierungsformen | |
| EE05404B1 (et) | Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nhtud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| EA200870325A1 (ru) | Лекарственные формы для введения комбинаций лекарственных средств | |
| EA200300503A1 (ru) | Новые лекарственные композиции на основе солей тиотропия и солей салметерола | |
| CY1107373T1 (el) | Απ’ ευθειας συμπιεσιμη φαρμακευτικη συνθεση για τη στοματικη χορηγηση του cci-779 | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| DK1256339T3 (da) | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| BRPI0414500A (pt) | formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais | |
| HUP0202776A2 (hu) | (+)-Tramadol, O-demetil-tramadol, (+)-O-demetil-tramadol, O-demetil-N-mono-demetil-tramadol, illetve (+)-O-demetil-N-mono-demetil-tramadol felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására | |
| DE60107399D1 (de) | Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin | |
| ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| EA200401303A1 (ru) | Лекарственные средства, содержащие стероиды и новое антихолинергическое средство | |
| ATE400257T1 (de) | Stabile pharmazeutische zusammensetzung mit linezolid form iv | |
| EA200501223A1 (ru) | Терапевтическая система, содержащая амоксициллин и клавулановую кислоту | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| RU2010146309A (ru) | Фармацевтическая композиция для лечения фибромиалгии | |
| GEP201606538B (en) | Preoperative treatment of post operative pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |